Your browser doesn't support javascript.
loading
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney, Jason; Lewis, Karl D; Kluger, Harriet; Hamid, Omid; Whitman, Eric; Thomas, Sajeve; Wermke, Martin; Cusnir, Mike; Domingo-Musibay, Evidio; Phan, Giao Q; Kirkwood, John M; Hassel, Jessica C; Orloff, Marlana; Larkin, James; Weber, Jeffrey; Furness, Andrew J S; Khushalani, Nikhil I; Medina, Theresa; Egger, Michael E; Graf Finckenstein, Friedrich; Jagasia, Madan; Hari, Parameswaran; Sulur, Giri; Shi, Wen; Wu, Xiao; Sarnaik, Amod.
Afiliación
  • Chesney J; Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
  • Lewis KD; Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, USA.
  • Kluger H; Medical Oncology, Hematology & Oncology, Melanoma and Onco-Dermatology, Genitourinary Oncology, Yale New Haven Health Smilow Cancer Hospital, New Haven, Connecticut, USA.
  • Hamid O; Hematology Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, USA.
  • Whitman E; Atlantic Health System Cancer Care, Morristown, New Jersey, USA.
  • Thomas S; Hematology and Oncology, Orlando Health Cancer Institute, Orlando, Florida, USA.
  • Wermke M; Technische Universität Dresden - NCT/UCC Early Clinical Trial Unit, Dresden, Sachsen, Germany.
  • Cusnir M; Division of Hematology & Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
  • Domingo-Musibay E; Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
  • Phan GQ; Surgery, Virginia Commonwealth University, Massey Cancer Center, Richmond, Virginia, USA.
  • Kirkwood JM; Medicine, Dermatology and Translational Science, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Hassel JC; Skin Cancer Center, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany.
  • Orloff M; Thomas Jefferson University Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, USA.
  • Larkin J; The Royal Marsden NHS Foundation Trust, London, UK.
  • Weber J; Department of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
  • Furness AJS; The Royal Marsden NHS Foundation Trust, London, UK.
  • Khushalani NI; Department of Cutaneous Oncology, H Lee Moffitt Cancer Center, Tampa, Florida, USA.
  • Medina T; Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, USA.
  • Egger ME; Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
  • Graf Finckenstein F; Iovance Biotherapeutics Inc, San Carlos, California, USA.
  • Jagasia M; Iovance Biotherapeutics Inc, San Carlos, California, USA.
  • Hari P; Iovance Biotherapeutics Inc, San Carlos, California, USA.
  • Sulur G; Iovance Biotherapeutics Inc, San Carlos, California, USA.
  • Shi W; Iovance Biotherapeutics Inc, San Carlos, California, USA.
  • Wu X; Iovance Biotherapeutics Inc, San Carlos, California, USA.
  • Sarnaik A; Department of Cutaneous Oncology, H Lee Moffitt Cancer Center, Tampa, Florida, USA amod.sarnaik@moffitt.org.
J Immunother Cancer ; 10(12)2022 12.
Article en En | MEDLINE | ID: mdl-36600653
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido